Company History

Deerland Enzymes is deeply rooted in the history of enzymes, tracing its lineage back to Dr. Jokichi Takamine, the creator of the first digestive enzyme.

Deerland Enzymes was founded in 1990 by Richard DeSenna as an enzyme trading and consulting company. DeSenna worked for forty years in enzyme manufacturing, starting with Takamine Laboratories and Miles Labs who purchased Takamine Labs in the late 60’s. DeSenna held positions in enzyme manufacturing from Plant Operator at the Takamine plant in Clifton, New Jersey to V.P. of Operations for Miles where he had responsibility for the worldwide enzyme manufacturing and process development for ten enzyme facilities; four located in the U.S. and six international plants located in Germany, France, Argentina, Mexico and Japan.

In 1996, Hilton Dawson joined Deerland Enzymes to initiate marketing and technical service activities. With a technical background in chemistry and biochemistry, his enzyme career started in 1966 with Miles Laboratories (formerly Takamine Labs) conducting enzyme applications research. Dawson held a number of management positions with Miles in technical service, sales and worldwide marketing. When Solvay Enzymes, Inc. purchased the enzyme business from Bayer, Dawson continued with Solvay as Director of Marketing and Director of Market Development before joining DeSenna at Deerland Enzymes. Dawson is well known in the industry for his expertise on the biochemistry of enzymes as well as the process of manufacturing and research and development of new product applications, delivery, efficacy and integrity of individual formulations.

Through DeSenna’s network of global contacts established during his international career with Miles along with Dawson’s technical enzyme expertise, Deerland Enzymes quickly evolved into a leading international trading company. In 2006, the company was acquired by a privately owned company. In the late 2000s, Deerland’s focus shifted from purely manufacturing to include innovative enzyme based product development for human consumption. Scott Ravech was appointed CEO in 2008, while DeSenna and Dawson remained an active resource to the company.

Over the past 20 years, Deerland Enzymes has remained laser-focused on enzymes and new approaches to enzyme technology. Under the leadership of Ravech, the company began to further define its place in the market by establishing a strategy around four core areas: customization, industry alliances, technology, and education.

Unlike what had been done in the past during the initial growth of the enzyme supplement market, Deerland rejected the notion of a one-size-fits-all product formulation. Instead of reformulating the same basic enzymes into different products by simply varying the combinations and activities, the forward thinking leaders at Deerland determined that they could provide customized solutions for their customers through the innovative use of complementary technologies. They recognized that because enzyme functions vary widely, enzyme formulas along with components such as probiotics, prebiotics and other natural ingredients can target distinctive digestive or systemic conditions, ages, genders, etc. The company began to collaborate together with their customers in order to develop custom formulas for the specific performance benefits they were targeting. The industry quickly began to take notice of Deerland’s innovative approach to enzyme product formulation.

As a result, many talented individuals who had contributed to establishing the enzyme market from the beginning eventually joined Deerland Enzymes, including John Davidson, a 30-year veteran of the industry.

Ravech continued to build a team of unrivaled experience and depth of knowledge, adding to Deerland’s staff Dr. John Deaton, Ph.D. of Biochemistry. In 2010, Deerland entered into a joint product development alliance with Thione International, a healthcare technology company focusing on the development of enzyme based applications utilizing a powerful synergistic combination of technologies that lead to the creation of highly innovative digestive and antioxidant formulations. Through this alliance, Deerland gained an invaluable resource in highly respected gastroenterologist, Dr. Theodore Hersh, the head of Thione. The ongoing research and development initiatives at Deerland also included building alliances with top universities, collaborating through clinical research based on each institution’s specific area of expertise.

Building on the work of those who established the enzyme industry, the scientists at Deerland Enzymes are committed to taking the enzyme supplement industry to a new level of safety and efficacy.

timeline